echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP: Application of prescription opioids in multiple sclerosis

    JNNP: Application of prescription opioids in multiple sclerosis

    • Last Update: 2022-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pain can be one of the most severe symptoms of
    multiple sclerosis (MS).


    To identify patients with multiple sclerosis, we update the mood/anxiety disorder states (active versus inactive/absent)
    once a year.


    Includes 2918 MS patients and 14 539 non-MS patients
    .


    In the MS cohort, 25 percent of patients stopped taking opioids for an extended period of 12 days
    .


    Average annual age-stratified and sex-stratified incidence and prevalence of opioid use in MS and non-MS cohorts

    Opioid use
    in MS and non-MS patients was studied over 20 years.


    A U.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.